# Naveris

Source: https://onco.cc/companies/naveris/  
OnCo record `naveris` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Naveris makes NavDx, a blood test that tracks DNA from the HPV virus shed by tumours, so doctors can confirm HPV-related throat and anal cancers and catch them coming back after treatment. It was bought by CareDx in 2026.

## Summary

Naveris, based in Waltham, Massachusetts and founded in 2017, developed NavDx, a blood test that quantifies tumour tissue modified viral (TTMV) HPV DNA in plasma. The tumour-naive assay can confirm HPV-driven disease at diagnosis, assess treatment response and detect molecular residual disease (MRD) and recurrence in HPV-positive oropharyngeal and anal squamous cell carcinoma. The test runs in a CLIA-certified, CAP-accredited, New York State-approved laboratory. Medicare coverage began in 2023 with ADLT status at $1,800 per test; more than 130,000 commercial tests have been reported. Naveris raised an expanded Series A of $19 million in 2020 and $51 million in 2022, led by Gurnet Point Capital. CareDx agreed in April 2026 to acquire it for $160 million up front plus up to $100 million in milestones, closing in July 2026.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Waltham, MA
- Type: diagnostics
- Website: https://naveris.com/

## Notes

- 2022 release dateline is Natick, MA; the current website gives Waltham, MA. Anal cancer has no id in the cancer list. NavDx is a laboratory developed test; no FDA clearance is claimed here.

## Sources

- Official website: https://naveris.com/
- CareDx 8-K exhibit: agreement to acquire Naveris (Apr 2026): https://www.sec.gov/Archives/edgar/data/1217234/000110465926050317/tm2611749d3_ex99-2.htm
- CareDx completes acquisition (Jul 2026): https://www.sec.gov/Archives/edgar/data/1217234/000121723426000038/naveris-pressrelease.htm
- $51 million financing (Sep 2022): https://naveris.com/naveris-inc-raises-51-million-to-advance-commercialization-of-navdx/

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- companies: [ACS BrightEdge (American Cancer Society)](https://onco.cc/companies/acs-brightedge/)

---
JSON: https://onco.cc/api/v1/entities/naveris.json